Danaher (DHR) Stock Overview
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DHR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Danaher Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$186.95 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.96 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 143.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| DHR | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | 3.1% |
| 1Y | n/a | -12.4% | 6.7% |
Return vs Industry: Insufficient data to determine how DHR performed against the Swiss Life Sciences industry.
Return vs Market: Insufficient data to determine how DHR performed against the Swiss Market.
Price Volatility
| DHR volatility | |
|---|---|
| DHR Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 4.9% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 9.0% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: DHR's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine DHR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 60,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
Danaher Corporation Fundamentals Summary
| DHR fundamental statistics | |
|---|---|
| Market cap | CHF 120.59b |
| Earnings (TTM) | CHF 2.80b |
| Revenue (TTM) | CHF 19.09b |
Is DHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHR income statement (TTM) | |
|---|---|
| Revenue | US$24.57b |
| Cost of Revenue | US$10.05b |
| Gross Profit | US$14.52b |
| Other Expenses | US$10.92b |
| Earnings | US$3.60b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.09 |
| Gross Margin | 59.11% |
| Net Profit Margin | 14.65% |
| Debt/Equity Ratio | 35.1% |
How did DHR perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 00:36 |
| End of Day Share Price | 2025/12/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Danaher Corporation is covered by 41 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |